Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Sept 2026

Clemente-Suárez Vicente Javier, Olivares Rodrigo, Yáñez-Sepúlveda Rodrigo, Guzmán-Muñóz Eduardo, Rodríguez Alexandra Martín

Abstract excerpt

BACKGROUND: The prognostic relevance of ultra-rare TP53 and KRAS variants in advanced solid tumours treated with immune-checkpoint inhibitors (ICI) is unclear. METHODS: We performed a retrospective cohort study using the Memorial Sloan Kettering Cancer Center MSK-IMPACT clinical-genomic dataset (cBioPortal study ID: tmb_mskcc_2018). TP53 and KRAS alterations were stratified by rarity (ultra-rare vs common) and...

Topics

Join the communities discussing this publication.

Carcinoma, Non-Small-Cell Lung
Immune Checkpoint Inhibitors
Kaplan-Meier Estimate
Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Oncogene Protein p21(ras)

Proto-Oncogene Proteins p21(ras)

Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41860684
DOI: 10.1007/s12094-026-04319-3

Genes

KRAS
TP53
IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours.PMID 41860684Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity Read ↗

Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.Semantic proximity Read ↗

The Mutational Landscape of TP53 in Pakistani Cancer Cohorts: A Systematic Review and Proportion Meta-Analysis for Precision Oncology TargetsSemantic proximity Read ↗

The Mutational Landscape of TP53 in Pakistani Cancer Cohorts: A Systematic Review and Proportion Meta-Analysis for Precision Oncology TargetsSemantic proximity Read ↗

Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.Semantic proximity Read ↗

The effects of common genetic variants in oncogenes on ovarian cancer survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.